Pink Sheet reports on Aranesp and Procrit concerns

Share this content:
Members of the FDA's Oncologic Drugs Advisory Committee expressed concerns at a May meeting that DTC advertising of Amgen's Aranesp and Johnson & Johnson's Procrit have given patients a lopsided impression of the drugs' risk/benefit profile, The Pink Sheet reported. The state of New York subpoenaed Aranesp promotional materials that month.
Share this content:
Scroll down to see the next article